Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKTURNA HCT vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aliskiren is a direct renin inhibitor that decreases plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Hypertension (to lower blood pressure, either as initial therapy or in patients not adequately controlled on monotherapy)
Hypertension
Oral: 1 tablet (aliskiren 150 mg / hydrochlorothiazide 12.5 mg) once daily. If blood pressure not controlled, may increase to 1 tablet (aliskiren 300 mg / hydrochlorothiazide 12.5 mg) or 1 tablet (aliskiren 300 mg / hydrochlorothiazide 25 mg) once daily.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Aliskiren: terminal half-life 24-31 hours (accumulation supports once-daily dosing). Hydrochlorothiazide: 6-15 hours (correlates with duration of action).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Aliskiren is primarily metabolized by CYP3A4; Hydrochlorothiazide is not metabolized and excreted unchanged in urine.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Aliskiren: 78-91% unchanged in feces via biliary excretion, <2.4% in urine. Hydrochlorothiazide: ≥95% renal, 50-75% unchanged.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Aliskiren: 47-51% (albumin). Hydrochlorothiazide: 40-68% (albumin).
Approximately 70-80% bound to plasma proteins, primarily albumin.
Aliskiren: 0.65-2.3 L/kg (extensive tissue distribution due to lipophilicity). Hydrochlorothiazide: 3-7 L/kg (distributes into erythrocytes).
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Aliskiren: 2-5% oral (1.6-2.8% at 300 mg). Hydrochlorothiazide: 65-70% oral.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Contraindicated in patients with GFR <30 m L/min/1.73m2. For GFR 30-59 m L/min/1.73m2: no dose adjustment required, but monitor serum potassium and creatinine. Discontinue if progressive oliguria or acute renal failure occurs.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: use with caution; no specific dose guidelines.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Safety and efficacy not established in pediatric patients less than 18 years of age.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Elderly patients may be more sensitive to hypotension and electrolyte imbalances. Start at the lowest dose (150/12.5 mg) and titrate cautiously. Monitor renal function and electrolytes regularly.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
Avoid use in pregnancy (especially 2nd and 3rd trimesters) due to fetal toxicity; discontinue immediately if pregnancy occurs.,Not recommended with ACE inhibitors or ARBs in patients with diabetes or renal impairment (Cr Cl < 60 m L/min) due to increased risk of renal dysfunction, hyperkalemia, and hypotension.,Symptomatic hypotension may occur, especially in volume-depleted patients; correct volume depletion before use.,Electrolyte imbalances: monitor serum potassium (risk of hyperkalemia), sodium, and magnesium; hydrochlorothiazide may cause hypokalemia, hyponatremia, and hypomagnesemia.,Renal impairment: monitor renal function; may cause acute renal failure; contraindicated with Cr Cl < 30 m L/min for hydrochlorothiazide component.,Angioedema may occur; discontinue if develops.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Pregnancy (risk of fetal harm),Anuria (due to hydrochlorothiazide component),Concomitant use with ACE inhibitors or ARBs in patients with diabetes mellitus or moderate-to-severe renal impairment (Cr Cl < 60 m L/min),Hypersensitivity to any component (including sulfonamide-derived drugs for hydrochlorothiazide)
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid high-potassium foods (bananas, oranges, spinach, potatoes) and potassium-containing salt substitutes. Limit sodium intake to assist antihypertensive effect. Grapefruit juice may reduce aliskiren absorption; avoid concurrent consumption.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: Drugs acting directly on the renin-angiotensin system (aliskiren, the aliskiren component) can cause fetal renal dysfunction, oligohydramnios, and skull ossification defects. Second and third trimesters: Exposure is associated with fetal hypotension, anuria, renal failure, oligohydramnios, skull hypoplasia, and death. Hydrochlorothiazide: Crosses the placenta; risk of electrolyte disturbances, jaundice, and thrombocytopenia in the newborn. Generally avoid in pregnancy, especially second and third trimesters.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Aliskiren: Not known if excreted in human milk. Hydrochlorothiazide: Excreted in breast milk in small amounts; M/P ratio not reported. Use with caution, monitor infant for dehydration, electrolyte imbalance. Consider alternatives if possible.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Avoid use during pregnancy. If exposure occurs, discontinue as soon as possible. No recommended dose adjustments; alternative agents are preferred. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, renal clearance) may reduce drug efficacy, but no specific dose adjustment studies exist for this combination.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Tekturna HCT is a fixed-dose combination of aliskiren (renin inhibitor) and hydrochlorothiazide (thiazide diuretic). Avoid use in pregnancy (category D). Monitor renal function and serum electrolytes, especially potassium and sodium, as aliskiren can increase potassium and HCTZ can cause hypokalemia. Contraindicated with concomitant use of ARBs or ACE inhibitors in patients with diabetes or renal impairment (e GFR <60 m L/min/1.73 m²). Assess for hypotension, especially in volume-depleted patients. Max antihypertensive effect may take 2-4 weeks.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Do not take if pregnant or planning to become pregnant; use effective contraception.,Avoid potassium supplements, salt substitutes, or high-potassium foods without consulting your doctor.,Take exactly as prescribed; do not skip doses or double up.,May cause dizziness; avoid driving until you know how the medication affects you.,Drink adequate fluids to prevent dehydration, especially in hot weather or with exercise.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst, or confusion.,Avoid alcohol as it may increase blood pressure-lowering effects and dizziness.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKTURNA HCT vs ALDOCLOR-150, answered by our medical review team.
TEKTURNA HCT is a Antihypertensive combination that works by Aliskiren is a direct renin inhibitor that decreases plasma renin activity and inhibits the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKTURNA HCT and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKTURNA HCT is: Oral: 1 tablet (aliskiren 150 mg / hydrochlorothiazide 12.5 mg) once daily. If blood pressure not controlled, may increase to 1 tablet (aliskiren 300 mg / hydrochlorothiazide 12.5 mg) or 1 tablet (aliskiren 300 mg / hydrochlorothiazide 25 mg) once daily.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKTURNA HCT and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKTURNA HCT is classified as Category C. First trimester: Drugs acting directly on the renin-angiotensin system (aliskiren, the aliskiren component) can cause fetal renal dysfunction, oligohydramnios, and skull ossificati. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.